About: Neutralizing Antibody Responses in COVID-19 Convalescent Sera

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Neutralizing Antibody Responses in COVID-19 Convalescent Sera Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Neutralizing Antibody Responses in COVID-19 Convalescent Sera
Creator	Krammer, Florian Wong, Susan Taylor, Jill Lee, William Dupuis Ii, Alan Amler, Sherlita Arinsburg, Suzanne Cordon-Cardo, Carlos Firpo-Betancourt, Adolfo Girardin, Roxanne Gov, William Hutton, Brad Jhang, Jeffrey Kulas, Karen Mcdonough, Kathleen Montecalvo, Marisa Nguyen, Freddy Payne, Rao, Damodara Wajnberg, Ania
Source	MedRxiv
abstract	Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration's (FDA) guidelines for convalescent plasma recommends target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at low (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was ~93% (PRNT50) and ~54% (PRNT90). Sera with high SARS-CoV-2 antibody levels ([≥]960 ELISA titers) showed maximal activity, but not all high titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
has issue date	2020-07-11(xsd:dateTime)
bibo:doi	10.1101/2020.07.10.20150557
has license	medrxiv
sha1sum (hex)	942f3203f2535a91ee837a28ae4bfe529f83e25a
schema:url	https://doi.org/10.1101/2020.07.10.20150557
resource representing a document's title	Neutralizing Antibody Responses in COVID-19 Convalescent Sera
resource representing a document's body	covid:942f3203f2535a91ee837a28ae4bfe529f83e25a#body_text
is schema:about of	named entity 'Responses' named entity 'Antibody' named entity 'reuse' named entity 'IgG' named entity 'SARS-CoV' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'preprint' named entity 'preprint' named entity 'Vero E6' named entity 'virus' named entity 'medRxiv' named entity 'viral plaque' named entity 'preprint' named entity 'preprint' named entity 'doi' named entity 'peer review' named entity 'streptavidin' named entity 'medRxiv' named entity 'preprint' named entity 'Mount Sinai' named entity 'ectodomain' named entity 'peer review' named entity 'recombinant' named entity 'doi' named entity 'viruses' named entity 'symptom' named entity 'immune response' named entity 'antibody' named entity 'peer review' named entity 'peer review' named entity 'peer review' named entity 'serum' named entity 'medRxiv' named entity 'FDA' named entity 'antigen' named entity 'convalescent plasma' named entity 'FDA' named entity 'peer review' named entity 'polystyrene' named entity 'medRxiv' named entity 'medRxiv' named entity 'RBD' named entity 'preprint' named entity 'phycoerythrin' named entity 'preprint' named entity 'preprint' named entity 'patent protection' named entity 'medRxiv' named entity 'peer review' named entity 'neutralizing antibodies' named entity 'SARS-CoV-2' named entity 'antigen' named entity 'receptor binding domain' named entity 'medRxiv' named entity 'SARS-CoV-2' named entity 'RBD' named entity 'convalescent plasma' named entity 'protein' named entity 'CO2' named entity 'preprint' named entity 'medRxiv' named entity 'nucleoprotein' named entity 'spike protein' named entity 'serum'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software